200 related articles for article (PubMed ID: 31461725)
1. Correlation between Automated Bone Scan Index Change after Cabazitaxel and Survival among Men with Castration-Resistant Prostate Cancer.
Miyoshi Y; Sakamoto S; Kawahara T; Uemura K; Yokomizo Y; Uemura H
Urol Int; 2019; 103(3):279-284. PubMed ID: 31461725
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of an automated bone scan index for men with metastatic castration-resistant prostate cancer treated with cabazitaxel.
Uemura K; Miyoshi Y; Kawahara T; Ryosuke J; Yamashita D; Yoneyama S; Yokomizo Y; Kobayashi K; Kishida T; Yao M; Uemura H
BMC Cancer; 2018 May; 18(1):501. PubMed ID: 29716525
[TBL] [Abstract][Full Text] [Related]
3. Risk Factors for Poor Survival in Metastatic Castration-resistant Prostate Cancer Treated With Cabazitaxel in Japan.
Yasuoka S; Yuasa T; Ogawa M; Komai Y; Numao N; Yamamoto S; Kondo Y; Yonese J
Anticancer Res; 2019 Oct; 39(10):5803-5809. PubMed ID: 31570485
[TBL] [Abstract][Full Text] [Related]
4. PSA response to cabazitaxel is associated with improved progression-free survival in metastatic castration-resistant prostate cancer: the non-interventional QoLiTime study.
Hammerer P; Al-Batran SE; Windemuth-Kieselbach C; Keller M; Hofheinz RD
World J Urol; 2018 Mar; 36(3):375-381. PubMed ID: 29305637
[TBL] [Abstract][Full Text] [Related]
5. Prostate-specific antigen flare induced by cabazitaxel-based chemotherapy in patients with metastatic castration-resistant prostate cancer.
Angelergues A; Maillet D; Fléchon A; Ozgüroglu M; Mercier F; Guillot A; Le Moulec S; Gravis G; Beuzeboc P; Massard C; Fizazi K; de La Motte Rouge T; Delanoy N; Elaidi RT; Oudard S
Eur J Cancer; 2014 Jun; 50(9):1602-9. PubMed ID: 24725337
[TBL] [Abstract][Full Text] [Related]
6. Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial.
Beer TM; Hotte SJ; Saad F; Alekseev B; Matveev V; Fléchon A; Gravis G; Joly F; Chi KN; Malik Z; Blumenstein B; Stewart PS; Jacobs CA; Fizazi K
Lancet Oncol; 2017 Nov; 18(11):1532-1542. PubMed ID: 29033099
[TBL] [Abstract][Full Text] [Related]
7. Serum and hematologic responses after three cycles of cabazitaxel therapy as predictors of survival in castration-resistant prostate cancer.
Fujiwara M; Yuasa T; Yasuoka S; Komai Y; Oguchi T; Fujiwara R; Numao N; Yamamoto S; Yonese J
Cancer Chemother Pharmacol; 2021 Sep; 88(3):525-531. PubMed ID: 34110449
[TBL] [Abstract][Full Text] [Related]
8. Assessing Radiographic Response to
Anand A; Trägårdh E; Edenbrandt L; Beckman L; Svensson JH; Thellenberg C; Widmark A; Kindblom J; Ullén A; Bjartell A
J Nucl Med; 2020 May; 61(5):671-675. PubMed ID: 31586004
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of cabazitaxel and the influence of clinical factors on the overall survival of patients with castration-resistant prostate cancer: A local experience of a multicenter retrospective study.
Takai M; Kato S; Nakano M; Fujimoto S; Iinuma K; Ishida T; Taniguchi M; Tamaki M; Uno M; Takahashi Y; Komeda H; Koie T
Asia Pac J Clin Oncol; 2021 Jun; 17(3):238-244. PubMed ID: 32970933
[TBL] [Abstract][Full Text] [Related]
10. No significant impact of patient age and prior treatment profile with docetaxel on the efficacy of cabazitaxel in patient with castration-resistant prostate cancer.
Kosaka T; Hongo H; Watanabe K; Mizuno R; Kikuchi E; Oya M
Cancer Chemother Pharmacol; 2018 Dec; 82(6):1061-1066. PubMed ID: 30283980
[TBL] [Abstract][Full Text] [Related]
11. Optimal Timing of Cabazitaxel Introduction for Japanese Patients With Metastatic Castration-resistant Prostate Cancer.
Ito T; Kanao K; Takahara K; Ando R; Yasui T; Shiroki R; Sumitomo M; Miyake H
Anticancer Res; 2019 Jun; 39(6):3089-3094. PubMed ID: 31177153
[TBL] [Abstract][Full Text] [Related]
12. The efficacy and toxicity of cabazitaxel for treatment of docetaxel-resistant prostate cancer correlating with the initial doses in Japanese patients.
Terada N; Kamoto T; Tsukino H; Mukai S; Akamatsu S; Inoue T; Ogawa O; Narita S; Habuchi T; Yamashita S; Mitsuzuka K; Arai Y; Kandori S; Kojima T; Nishiyama H; Kawamura Y; Shimizu Y; Terachi T; Sugi M; Kinoshita H; Matsuda T; Yamada Y; Yamamoto S; Hirama H; Sugimoto M; Kakehi Y; Sakurai T; Tsuchiya N
BMC Cancer; 2019 Feb; 19(1):156. PubMed ID: 30770773
[TBL] [Abstract][Full Text] [Related]
13. No significant impact of prior treatment profile with docetaxel on the efficacy of cabazitaxel in Japanese patients with metastatic castration-resistant prostate cancer.
Miyake H; Sugiyama T; Aki R; Matsushita Y; Tamura K; Motoyama D; Ito T; Otsuka A
Med Oncol; 2017 Aug; 34(8):141. PubMed ID: 28718092
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of a computer-aided diagnosis system involving bone scans among men treated with docetaxel for metastatic castration-resistant prostate cancer.
Uemura K; Miyoshi Y; Kawahara T; Yoneyama S; Hattori Y; Teranishi J; Kondo K; Moriyama M; Takebayashi S; Yokomizo Y; Yao M; Uemura H; Noguchi K
BMC Cancer; 2016 Feb; 16():109. PubMed ID: 26883015
[TBL] [Abstract][Full Text] [Related]
15. Quality of life and pain relief in men with metastatic castration-resistant prostate cancer on cabazitaxel: the non-interventional 'QoLiTime' study.
Hofheinz RD; Lange C; Ecke T; Kloss S; Linsse B; Windemuth-Kieselbach C; Hammerer P; Al-Batran SE
BJU Int; 2017 May; 119(5):731-740. PubMed ID: 27618249
[TBL] [Abstract][Full Text] [Related]
16. An observational, multicentre study of cabazitaxel in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (CAPRISTANA).
Carles J; Pichler A; Korunkova H; Tomova A; Ghosn M; El Karak F; Makdessi J; Koroleva I; Barnes G; Bury D; Özatilgan A; Hitier S; Katolicka J
BJU Int; 2019 Mar; 123(3):456-464. PubMed ID: 30098093
[TBL] [Abstract][Full Text] [Related]
17. Real-world efficacy and safety of two doses of cabazitaxel (20 or 25 mg/m
Matsuyama H; Matsubara N; Kazama H; Seto T; Tsukube S; Suzuki K
BMC Cancer; 2020 Jul; 20(1):649. PubMed ID: 32660451
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of grade 3/4 neutropenia in Japanese prostate cancer patients treated with cabazitaxel.
Kosaka T; Shinojima T; Morita S; Oya M
Cancer Sci; 2018 May; 109(5):1570-1575. PubMed ID: 29493842
[TBL] [Abstract][Full Text] [Related]
19. Treatment selection for men with metastatic prostate cancer who progress on upfront chemo-hormonal therapy.
Barata P; Emamekhoo H; Mendiratta P; Koshkin V; Tyler A; Ornstein M; Rini BI; Gilligan T; Kyriakopoulos C; Garcia JA
Prostate; 2018 Sep; 78(13):1035-1041. PubMed ID: 29882332
[TBL] [Abstract][Full Text] [Related]
20. Phase 3 Assessment of the Automated Bone Scan Index as a Prognostic Imaging Biomarker of Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Armstrong AJ; Anand A; Edenbrandt L; Bondesson E; Bjartell A; Widmark A; Sternberg CN; Pili R; Tuvesson H; Nordle Ö; Carducci MA; Morris MJ
JAMA Oncol; 2018 Jul; 4(7):944-951. PubMed ID: 29799999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
